AFC-HD AMS Life Science Co., Ltd. (TYO:2927)
Japan · Delayed Price · Currency is JPY 874.00
+32.00 (3.80%)
Oct 16, 2026, 3:30 PM JST
AFC-HD AMS Life Science Income Statement
Financials in millions JPY. Fiscal year is September - August.
Millions JPY. Fiscal year is Sep - Aug.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 31, 2026 | Aug '25 Aug 31, 2025 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 |
| 34,324 | 32,655 | 30,185 | 25,579 | 22,997 | |
Revenue Growth | 5.11% | 8.18% | 18.01% | 11.23% | 2.81% |
Cost of Revenue | 22,402 | 21,394 | 19,694 | 16,256 | 14,418 |
Gross Profit | 11,922 | 11,261 | 10,491 | 9,323 | 8,579 |
Selling, General & Admin | 9,466 | 8,529 | 8,349 | 7,526 | 7,415 |
Amortization of Goodwill & Intangibles | - | 291 | 222 | 160 | 152 |
Other Operating Expenses | - | 32 | - | - | - |
Operating Expenses | 9,466 | 8,851 | 8,575 | 7,686 | 7,567 |
Operating Income | 2,456 | 2,410 | 1,916 | 1,637 | 1,012 |
Interest Expense | -266 | -201 | -101 | -57 | -57 |
Interest & Investment Income | 32 | 24 | 10 | 16 | 16 |
Other Non Operating Income (Expenses) | 148 | 129 | 11 | 21 | 356 |
EBT Excluding Unusual Items | 2,370 | 2,362 | 1,836 | 1,617 | 1,327 |
Gain (Loss) on Sale of Investments | 18 | 12 | 69 | 36 | 11 |
Gain (Loss) on Sale of Assets | -437 | -2 | 38 | - | - |
Asset Writedown | -6 | -423 | -15 | -31 | -88 |
Other Unusual Items | 22 | 251 | -17 | -77 | -16 |
Pretax Income | 1,967 | 2,200 | 1,911 | 1,545 | 1,234 |
Income Tax Expense | 768 | 732 | 665 | 439 | 497 |
Earnings From Continuing Operations | 1,199 | 1,468 | 1,246 | 1,106 | 737 |
Minority Interest in Earnings | -1 | -20 | 6 | -4 | -2 |
Net Income | 1,198 | 1,448 | 1,252 | 1,102 | 735 |
Net Income to Common | 1,198 | 1,448 | 1,252 | 1,102 | 735 |
Net Income Growth | -17.27% | 15.65% | 13.61% | 49.93% | -50.84% |
Shares Outstanding (Basic) | 14 | 14 | 14 | 14 | 14 |
Shares Outstanding (Diluted) | 14 | 14 | 14 | 14 | 14 |
Shares Change | 2.81% | 0.12% | -0.01% | -0.47% | 0.36% |
EPS (Basic) | 82.83 | 102.94 | 89.19 | 78.47 | 52.31 |
EPS (Diluted) | 82.83 | 102.94 | 89.11 | 78.46 | 52.08 |
EPS Growth | -19.54% | 15.52% | 13.57% | 50.65% | -51.01% |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 31, 2026 | Aug '25 Aug 31, 2025 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 |
Free Cash Flow | - | -1,752 | -1,866 | -1,074 | 535 |
Free Cash Flow Per Share | - | -124.54 | -132.80 | -76.43 | 37.89 |
Dividend Per Share | - | 34.000 | 30.000 | 27.500 | 30.000 |
Dividend Growth | - | 13.33% | 9.09% | -8.33% | 9.09% |
Gross Margin | 34.73% | 34.48% | 34.76% | 36.45% | 37.30% |
Operating Margin | 7.16% | 7.38% | 6.35% | 6.40% | 4.40% |
Profit Margin | 3.49% | 4.43% | 4.15% | 4.31% | 3.20% |
Free Cash Flow Margin | - | -5.37% | -6.18% | -4.20% | 2.33% |
EBITDA | 3,852 | 3,806 | 3,000 | 2,620 | 2,017 |
EBITDA Margin | 11.22% | 11.65% | 9.94% | 10.24% | 8.77% |
D&A For EBITDA | 1,396 | 1,396 | 1,084 | 983 | 1,005 |
EBIT | 2,456 | 2,410 | 1,916 | 1,637 | 1,012 |
EBIT Margin | 7.16% | 7.38% | 6.35% | 6.40% | 4.40% |
Effective Tax Rate | 39.04% | 33.27% | 34.80% | 28.41% | 40.28% |
Advertising Expenses | - | 781 | 687 | 748 | 736 |